期刊文献+

彩色多普勒超声在乳腺癌新辅助化疗疗效评价上的应用价值 被引量:14

Value of color Doppler ultrasonography in evaluating effect of neoadjuvant chemotherapy for breast carcinoma
下载PDF
导出
摘要 目的:应用彩色多普勒超声探讨其在乳腺癌新辅助化疗疗效评价上的应用价值。方法:利用彩色多普勒超声对43例接受新辅助化疗的乳腺癌病灶的化疗疗效进行评价。结果:彩色多普勒超声检查评价乳腺癌病灶变化与病理学评价的符合率为72.09%,敏感度为86.36%,在病理判定有效组,新辅助化疗前后病灶内血流分级类型及RI值变化均具有显著性差异(PS<0.05);在病理判定无变化组,新辅助化疗前后病灶内血流分级类型及RI值变化均不具有显著性差异(PS>0.05)。结论:彩色多普勒超声检查乳腺癌病灶的二维图像及血流信息,能对乳腺癌新辅助化疗后的疗效做出客观评价,具有一定的临床应用价值。
出处 《中国临床医学影像杂志》 CAS 北大核心 2011年第12期876-878,共3页 Journal of China Clinic Medical Imaging
  • 相关文献

参考文献6

  • 1Smith IC,Heys SD,Hutcheon AW,et al.Neoadjuvant chemotherapy in breast cancer:significantly enhanced response with docetaxel[J].J Clin Oncol,2002,20(6):1456-1466.
  • 2Alder DD,Carson PL,Rubin JM,et al.Doppler ultrasound flow imaging in the study of breast cancer:preliminary findings[J].Ultrasound Med Biol,1990,16(6):553-559.
  • 3王殊,张嘉庆,乔新民,杨德启,佟富中.新辅助化疗后乳腺癌病理变化31例分析[J].中国妇产科临床杂志,2007,8(4):282-284. 被引量:7
  • 4Partridge SC,Gibbs JE,Lu Y,et al.Accuracy of MR imaging forrevealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy[J].AJR,2002,179 (5):1193-1199.
  • 5Moon WK,Im JG,Nob DY,et al.Nonpalpable breast lesions:evaluation with power Doppler US and a microbubble contrast agentinitial experience[J].Radiology,2000,217(1):240-246.
  • 6Lee SW,Choi HY,Baek SY,et al.Role of color and power Doppler imaging in differentiating between malignant and benign solid breast masses[J].J Clin Ultrasound,2002,30(8):459-464.

二级参考文献8

  • 1[1]Mamounas EP,Fisher B.Preoperative (neoadjuvant) chemotherapy in patients with breast cancer.Semin Oncol,2001,28:389-399.
  • 2[2]van der Hage JA,van de Velde CJ,Julien JP,et al.Preoperative chemotherapy in primary operable breast cancer:results from the European Organization for Research and Treatment of Cancer trial 10902.J Clin Oncol,2001,19:4224 -4237.
  • 3[3]Wolmark N,Wang J,Mamounas E,et al.Preoperative chemotherapy in patients with operable breast cancer:nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18.J Natl Cancer Inst Monogr,2001,30:96-102.
  • 4[4]Bonadonna G,Valagussa P,Brambilla C,et al.Primary chemotherapy in operable breast cancer:eight-year experience at the Milan Cancer Institute.J Clin Oncol,1998,16:93-100.
  • 5[5]Fisher B,Bryant J,Wolmark N,et al.Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.J Clin Oncol,1998,16:2672-2685.
  • 6[6]Kuerer HM,Sahin AA,Hunt KK,et al.Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvantchemotherapy.Ann Surg,1999,230:72-78.
  • 7[7]Lenert JT,Vlastos G,Mirza NQ,et al.Primary tumor response to induction chemotherapy as a predictor of histological status of axillary nodes in operable breast cancer patients.Ann Surg Oncol,1999,6:762-767.
  • 8[8]Pierga JY,Mouret E,Laurence V,et al.Prognostic factors for survival after neoadjuvant chemotherapy in operable breast cancer.the role of clinical response.Eur J Cancer,2003,39:1089-1096.

共引文献6

同被引文献122

引证文献14

二级引证文献70

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部